MTCR | Metacrine, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.4949 - 0.4949
52 Week Range	0.4949 - 0.4949
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	43,832,800
Market Cap	21,692,853
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-09-16

Valuation
Profitability
Growth
Health
P/E Ratio	-0.48
Forward P/E Ratio	N/A
EPS	-1.03
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	10
Country	USA
Website	MTCR

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

MTCR's peers: INDP, QLGN, TARA

*Chart delayed

Analyzing fundamentals for MTCR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see MTCR Fundamentals page.

Watching at MTCR technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on MTCR Technicals page.